AMARIN CORP PLC\UK Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
AMARIN CORP PLC\UK (AMRN) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 105.00 thousand shares for the 12-month period ending 2014-12-31, per its 10-K filed 2017-03-01.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2017-03-01
- AMARIN CORP PLC\UK incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2014-09-30 was 639.00K shares.
- AMARIN CORP PLC\UK incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2014-06-30 was 963.00K shares, a 84.83% decline year-over-year.
- AMARIN CORP PLC\UK incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2014-03-31 was 1.56M shares, a 23368.31% increase year-over-year.
- AMARIN CORP PLC\UK incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2013-06-30 was 6.35M shares.
- AMARIN CORP PLC\UK incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2014 was 105.00K shares, a 98.26% decline from fiscal 2013.
- AMARIN CORP PLC\UK incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2013 was 6.05M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month as first filed |
|---|---|---|---|---|---|---|
| 2014-12-31 | 105.00K shares 10-K · filed 2017-03-01 | |||||
| 2014-09-30 | 639.00K shares 10-Q · filed 2015-11-04 | 879.00K shares 10-Q · filed 2015-11-04 | ||||
| 2014-06-30 | 963.00K shares 10-Q · filed 2015-08-06 | 997.00K shares 10-Q · filed 2015-08-06 | ||||
| 2014-03-31 | 1.56M shares 10-Q · filed 2015-05-08 | 1.56K shares 10-Q · filed 2014-05-09 | ||||
| 2013-12-31 | 6.05M shares 10-K · filed 2016-02-25 | 6.05K shares 10-K · filed 2014-02-27 | ||||
| 2013-09-30 | 6.38M shares 10-Q · filed 2014-11-06 | |||||
| 2013-06-30 | 6.35M shares 10-Q · filed 2014-08-07 | 6.50M shares 10-Q · filed 2014-08-07 | ||||
| 2013-03-31 | 6.64K shares 10-Q · filed 2014-05-09 | |||||
| 2012-09-30 | 0.00 shares 10-Q · filed 2012-11-08 | 0.00 shares 10-Q · filed 2012-11-08 | ||||
| 2012-03-31 | 0.00 shares 10-Q · filed 2012-05-08 | |||||
| 2011-09-30 | 22.74M shares 10-Q · filed 2012-11-08 | 0.00 shares 10-Q · filed 2012-11-08 | ||||
| 2011-03-31 | 28.07M shares 10-Q · filed 2012-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |